Alltracel Pharmaceuticals Plc Announces a NanopeuticsTM Product and Technology Development License Agreement with HemCon Medical Technologies, Inc. to Serve the Military Market

Published: Jul 19, 2007

Alltracel Pharmaceuticals Plc., ("Alltracel", or "the Company"), (AIM:AP.L), the Healthcare Innovation Group focused on the Woundcare, Oral Care, Dermal Health and Cardiovascular Health markets, today announces its NanopeuticsTM subsidiary has signed a licensing agreement for its technology with HemCon Medical Technologies, Inc., the haemorrhage control market leaders in military markets.

Back to news